Drug Profile

Research programme: T-cell receptor-based natural killer cell therapies - Karolinska Institutet/Zelluna Immunotherapy

Alternative Names: Allogeneic TCR-NK therapies - Zelluna Immunotherapy/Karolinska Institutet

Latest Information Update: 28 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Karolinska Institute; Zelluna Immunotherapy
Class Immunotherapies; Natural killer cell therapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Apr 2024 No recent reports of development identified for research development in Solid-tumours in Norway (Parenteral)
12 Mar 2020 Early research in Solid tumours in Norway (Parenteral)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com